Equetro Web Pages Omit Risk Info, Make Unsupported Claims On Depression, FDA Says
This article was originally published in The Pink Sheet Daily
The agency sent Validus Pharmaceuticals a letter objecting to web pages that minimize the risk of suicidality with use of the bipolar disorder drug and suggest it does not worsen depression or induce weight gain.
You may also be interested in...
FDA says a chart on Biogen Indec’s website implies Avonex is superior to Copaxone, Rebif, Betaseron and Extavia; the notice of violation was issued the same day FDA sent a warning letter to Teva citing its Copaxone promos.
The first warning letter of the year from FDA’s Office of Prescription Drug Promotion goes to Teva for web pages and materials displayed at a medical conference that overstated the safety and efficacy of its MS drug Copaxone.
Website suggested that the unapproved cancer immunotherapy was safe and effective, FDA says.